CD8A and neoplasm: For instance, atezolizumab in combination with either T-DM1, or trastuzumab, or pertuzumab activates the adaptive immune response by exerting pressure on the tumor milieu, leading to the reinforcement in PD-L1 expression and CD8+ T-cell infiltration increase [103].